Clinical observation of LOP chemotherapy combined with radiotherapy in the treatment of early nasal NK/T cell lymphoma
-
摘要: 目的:探讨LOP(门冬酰胺酶+长春新碱+地塞米松)化疗联合放疗治疗鼻NK/T细胞淋巴瘤的疗效及其安全性。方法:选取2012-02-2016-02期间收治的60例鼻NK/T细胞淋巴瘤患者为研究对象,将其分为A组和B组,每组各30例。所有患者采用联合化疗与调强适形放疗(IMRT)相结合的综合治疗方案。A组化疗应用LOP方案,B组采用CHOP(环磷酰胺+吡柔比星+长春新碱+地塞米松)方案。比较2种不同诊疗方案的近期疗效、远期疗效以及不良反应情况。结果:60例患者的临床表现主要包括鼻塞(81.67%),并伴有发热、头痛、鼻出血以及流涕等。病变累及1个部位者41例(68.33%),累及多个部位者21例(35.00%)。在总缓解率方面,A组为93.33%,B组为66.67%,A组高于B组(P<0.05)。在不良反应发生率方面,A组在骨髓抑制、消化道反应、低蛋白反应方面的发生率均低于B组(P<0.05)。随访3年,A组共有3例患者死亡,B组共有11例患者死亡,A组的3年生存率高于B组(P<0.05)。结论:相较于CHOP+IMRT方案,采用LOP+IMRT方案对鼻NK/T细胞淋巴瘤患者进行治疗,其总缓解率和生存率更高,不良反应更低,值得推广。
-
关键词:
- 鼻NK/T细胞淋巴瘤 /
- 化学治疗 /
- 调强适形放疗 /
- 安全性
Abstract: Objective: To investigate the efficacy and safety of LOP(asparaginase + vincristine + dexamethasone) chemotherapy combined with radiotherapy in patients with nasal NK/T cell lymphoma. Method: Sixty patients with nasal NK/T cell lymphoma admitted to our hospital from February 2012 to February 2016 were selected as the study subject. They were randomly divided into group A and group B, 30 cases in each group. All patients were treated with combined chemotherapy and IMRT(intensity modulated conformal radiotherapy). The LOP regimen was used in group A and the CHOP(cyclophosphamide + pirarubicin + vincristine + dexamethasone) regimen was used in group B. The short-term efficacy, long-term efficacy and adverse reactions of the two groups were compared. Result: The clinical manifestations of 60 patients mainly included nasal obstruction(81.67%), accompanied by fever, headache, nosebleed and runny nose. Forty-one patients(68.33%) had only one site of lesion, and 21 patients(35.00%) had multiple sites of lesions. In terms of total remission rate, it was significantly higher in group A than that in group B(93.33% vs. 66.67%, P<0.05). In terms of adverse reactions, the incidence of bone marrow suppression, gastrointestinal reaction and low-protein reaction was significantly lower in group A than that in group B(P<0.05). Three patients died in group A and 11 patients died in group B during the 3-year follow-up. The 3-year survival rate of group A was higher than that of group B(P<0.05).Conclusion: Compared with CHOP+IMRT regimen, the LOP+IMRT regimen for nasal NK/T-cell lymphoma patients resulted in higher overall remission rate, survival rate and lower adverse reactions, so it is worth in clinical promotion. -
-
[1] 王雨晴,邓窈窕,张杰,等.结外鼻型NK/T细胞淋巴瘤首发症状与征与预后的关系[J].肿瘤研究与临床,2018,30(5):293-295.
[4] YAMAGUCHI M,SUZUKI R,OGUCHI M.Advances in the treatment of extranodal NK/T-cell lymphoma,nasal type[J].Blood,2018,131:2528-2540.
[5] LAHOUD O B.High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma[J].Am J Hematol,2018,6:40-46.
[6] 徐成,陈洁平,田小波,等.85例结外鼻型NK/T细胞淋巴瘤治疗及预后的回顾性观察[J].第三军医大学学报,2018,16(8):723-727.
[7] 丁志燕,黄彩虹,杨家佳,等.鼻腔自然杀伤/T细胞淋巴瘤患者临床病理分析[J].肿瘤研究与临床,2018,30(3):193-196.
[8] 李亚妮,王小娟,梁树辉,等.肠道结外鼻型NK/T细胞淋巴瘤临床特点及预后[J].现代肿瘤医学,2017,11(1):91-95.
[9] 夏林,蒋成义.鼻腔结外型NK/T细胞淋巴瘤治疗进展[J].国际耳鼻咽喉头颈外科杂志,2017,41(2):114-116.
[10] FEI Q,WEI H W,XIAO H H,et al.Phase Ⅱ study of first-line intensity modulated radio therapy(IMRT)followed by gemcitabine,dexamethasone,and cisplatin for high-risk early-stage extranodal nasal-type NK/T-cell lymphoma:the GREEN study[J].Int J Radiation Oncol Biol Physics,2018,102:61-70.
[11] 黄韵红,赵景辉,张盈,等.LOP方案同步联合IMRT治疗早期鼻NK/T细胞淋巴瘤的临床观察[J].中华医学杂志,2017,97(6):447-449.
-
计量
- 文章访问数: 300
- PDF下载数: 531
- 施引文献: 0